Centessa Pharmaceuticals plc (NASDAQ:CNTA) Short Interest Down 29.0% in May

Centessa Pharmaceuticals plc (NASDAQ:CNTA) was the recipient of a large decline in short interest in the month of May. As of May 31st, there was short interest totalling 1,250,000 shares, a decline of 29.0% from the May 15th total of 1,760,000 shares. Approximately 2.0% of the company’s stock are short sold. Based on an average daily trading volume, of 208,300 shares, the short-interest ratio is currently 6.0 days.

Wall Street Analysts Forecast Growth

Separately, BMO Capital Markets restated an “outperform” rating and set a $15.00 price objective on shares of Centessa Pharmaceuticals in a research note on Monday, April 1st. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Centessa Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Centessa Pharmaceuticals Stock Performance

CNTA stock traded up $0.25 on Friday, reaching $10.18. The company’s stock had a trading volume of 191,175 shares, compared to its average volume of 184,389. The company has a market capitalization of $1.02 billion, a P/E ratio of -7.17 and a beta of 1.39. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.37 and a quick ratio of 10.37. Centessa Pharmaceuticals has a 52 week low of $4.75 and a 52 week high of $12.45. The firm has a fifty day moving average of $9.41 and a two-hundred day moving average of $9.12.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03. As a group, analysts predict that Centessa Pharmaceuticals will post -1.71 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Karen M. Anderson sold 51,160 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $11.88, for a total transaction of $607,780.80. Following the completion of the sale, the insider now owns 71,525 shares of the company’s stock, valued at $849,717. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 11.59% of the stock is currently owned by insiders.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. raised its holdings in Centessa Pharmaceuticals by 69.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company’s stock worth $122,000 after buying an additional 4,423 shares during the period. Quarry LP acquired a new position in Centessa Pharmaceuticals in the fourth quarter worth approximately $48,000. EntryPoint Capital LLC bought a new position in shares of Centessa Pharmaceuticals during the 1st quarter valued at $109,000. Jump Financial LLC acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter worth about $114,000. Finally, Trexquant Investment LP bought a new stake in Centessa Pharmaceuticals during the fourth quarter worth approximately $114,000. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.